Boston Partners Purchases 16,601 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Boston Partners lifted its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 1.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,291,868 shares of the biopharmaceutical company’s stock after purchasing an additional 16,601 shares during the quarter. Boston Partners owned 1.08% of Catalyst Pharmaceuticals worth $27,325,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in CPRX. Intech Investment Management LLC grew its holdings in Catalyst Pharmaceuticals by 103.2% during the 4th quarter. Intech Investment Management LLC now owns 65,826 shares of the biopharmaceutical company’s stock worth $1,374,000 after acquiring an additional 33,431 shares during the last quarter. Cibc World Markets Corp bought a new stake in Catalyst Pharmaceuticals during the 4th quarter worth about $218,000. Globeflex Capital L P grew its holdings in Catalyst Pharmaceuticals by 319.8% during the 4th quarter. Globeflex Capital L P now owns 194,786 shares of the biopharmaceutical company’s stock worth $4,065,000 after acquiring an additional 148,388 shares during the last quarter. Natixis Advisors LLC grew its holdings in Catalyst Pharmaceuticals by 29.8% during the 4th quarter. Natixis Advisors LLC now owns 59,253 shares of the biopharmaceutical company’s stock worth $1,237,000 after acquiring an additional 13,616 shares during the last quarter. Finally, Commonwealth Equity Services LLC grew its holdings in Catalyst Pharmaceuticals by 133.1% during the 4th quarter. Commonwealth Equity Services LLC now owns 39,331 shares of the biopharmaceutical company’s stock worth $821,000 after acquiring an additional 22,455 shares during the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ:CPRX opened at $22.60 on Thursday. The company has a market capitalization of $2.74 billion, a price-to-earnings ratio of 19.15, a P/E/G ratio of 3.31 and a beta of 0.84. The firm’s 50 day simple moving average is $22.34 and its 200 day simple moving average is $21.57. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.47 and a fifty-two week high of $24.64.

Analyst Ratings Changes

A number of equities research analysts have commented on CPRX shares. Bank of America reissued a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Stephens reissued an “overweight” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Finally, Robert W. Baird raised their target price on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of “Buy” and an average price target of $32.50.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the sale, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Gary Ingenito sold 44,904 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the sale, the insider now owns 68,873 shares in the company, valued at $1,521,404.57. This trade represents a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.